# Lyell Immunopharma Announces Participation in May Investor Conferences
Canonical URL: https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-may-investor-conferences
Ticker: LYEL
Company: Lyell Immunopharma
Source: Lyell Immunopharma
Published: 2026-05-12 12:00 EST
Original Source URL: https://ir.lyell.com
## Summary

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior

## Article Body
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior
## Recent Company News
- 2026-06-01 12:00 EST — [Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-goldman-sachs-47th-annual-global-healthcare-conference-2026) — Source: Lyell Immunopharma
- 2026-05-12 12:00 EST — [Lyell Immunopharma Announces Participation in May Investor Conferences](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-may-investor-conferences) — Source: Lyell Immunopharma
- 2026-05-06 20:05 EST — [Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-first-quarter-2026) — Source: Lyell Immunopharma
- 2026-04-07 12:00 EST — [Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-25th-annual-needham-virtual-healthcare-conference) — Source: Lyell Immunopharma
- 2026-03-12 20:05 EST — [Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-reports-q4-and-full-year-2025-business-and-financial-results) — Source: Lyell Immunopharma
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)